GlassScriptPhysician profile
Fredric Zimmerman
NPI 1851322218
$591.14
in general payments reported to CMS, 2019-2025
22 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2021: $47.53 · 2023: $68.44 · 2024: $100 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.14 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $67.32 | 2019 | |
| Biodelivery Sciences International, INC. | $36.94 | 2019 | |
| Daiichi Sankyo INC. | $31.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.97 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.27 | 2023-2025 | Xifaxan, Trulance |
| Bioventus LLC | $26.66 | 2021 | |
| Aimmune Therapeutics, INC. | $22.87 | 2024 | |
| Averitas Pharma INC. | $22.77 | 2024 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $20.98 | 2024 | Rexulti |
| Amgen INC. | $20.87 | 2021 | |
| Novo Nordisk INC | $20.37 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $19.04 | 2023 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $19.04 | 2019 | |
| Lilly USA, LLC | $18.72 | 2024 | Zepbound, Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.70 | 2023 | Xarelto |
| Sumitomo Pharma America, INC. | $18.13 | 2025 | Gemtesa |
| Mdd US Operations, LLC | $17.45 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.33 | 2019 | |
| United Therapeutics Corporation | $16.43 | 2023 | Tyvaso |
| Allergan, INC. | $13.18 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.